Johnson & Johnson - Q1 2026 Earnings Analysis

Performance Highlights

Johnson & Johnson reported Q1 2026 sales of $24.1 billion, a 9.9% reported increase and 6.4% operationally, ahead of consensus, while adjusted diluted EPS of $2.70 came in above expectations despite a meaningful year-over-year decline from $2.77 in Q1 2025. GAAP net earnings fell 52.4% to $5.2 billion, largely reflecting the absence of the $7.3 billion other income benefit that inflated Q1 2025 results, rather than any deterioration in underlying operations.

Innovative Medicine drove the enterprise, posting 7.4% operational sales growth to $15.4 billion even as STELARA biosimilar competition imposed an approximately 920-basis-point headwind; oncology was the standout, growing 22.8% reported, led by DARZALEX share gains, rapid CARVYKTI site expansion, and RYBREVANT/LAZCLUZE launch momentum. MedTech contributed 4.6% operational growth to $8.6 billion, with cardiovascular the strongest platform at 10.5% operationally, powered by double-digit Abiomed Impella adoption and Shockwave coronary and peripheral portfolio strength.

Management Outlook and Forward Catalysts

Management raised 2026 operational sales guidance to a 5.9%–6.9% growth range (midpoint $100.8 billion) and lifted adjusted operational EPS guidance midpoint by $0.02 to a $11.30–$11.50 range, implying approximately 5.7% operational growth, while committing to at least 50 basis points of adjusted pre-tax operating margin expansion. The guidance increase, alongside a robust pipeline calendar including TREMFYA in psoriatic arthritis structural damage, DARZALEX in frontline transplant-ineligible myeloma, and the newly approved ICOTYDE oral IL-23R peptide for plaque psoriasis, signals that management views 2026 as a year of accelerating innovation-led growth rather than a period of biosimilar-driven consolidation.

The central debate for the next two quarters centres on whether newly launched oncology and immunology assets can sufficiently offset accelerating STELARA erosion and anticipated generic competition for OPSUMIT in the U.S. second half and SIMPONI in Europe; bulls will watch CARVYKTI capacity additions and ICOTYDE uptake as proof points, while bears will scrutinise MedTech margin compression — segment adjusted income before tax fell 7.6% year-over-year to 22.3% of sales — and China VBP headwinds expected to intensify in the second half.